Contract Research Organizations (CROs) are quickly becoming an integral part in the pharma industry owing to its ability to reduce risks and costs associated with clinical drug development. With an increase in the number of clinical trials, CROs aid pharma companies with their R&D process by saving resources, optimizing the development of drug and wearable device, and enhancing knowledge about the effects of the drugs.
The therapeutic area of CRO drives the pharmaceutical industry towards advanced research and development (R&D) of immuno-oncology drugs and treatments for metabolic diseases such as diabetes and glandular disorders. By continuously deploying cutting-edge technologies which include wearables and sensors in clinical trials, CROs add additional value into the R&D program. Further, these organizations are fusing their existing technology with recent technological discoveries such as Artificial Intelligence (AI) and nanotechnology to improve patient’s health and reduce the ever-increasing medical cost. Similarly, CROs are also inclining towards adaptive design which ensures that each adaptive trial offers an insight into how the design or R&D process can be enhanced for effective execution. These organizations also play an important role in closing the gap between real-world and clinical trial results of the drug by relying on technologies such as data analytics.
Aware of the current expansion and requirement of CROs in the pharmaceutical industry, a distinguished panel comprising of CEOs, CIOs, VCs, and analysts along with the editorial panel of Pharma Tech Outlook have indexed top 10 CROs of 2018 which are working towards developing extensive technology platforms for clinical trials.
We present to you Pharma Tech Outlook’s ‘Top 10 CROs - 2018.’
